Glycotope Doses First Patients in Phase IIb Study with PankoMab-GEX(TM) for the Maintenance Therapy of Ovarian Carcinoma - Seite 2

"The initiation of this Phase IIb trial is an important milestone for Glycotope, not only in the clinical development of PankoMab-GEX^TM but also for our comprehensive pipeline of cancer specific GlycoBodies," said Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope. "The results PankoMab-GEX^TM achieved already as single agent in a clinical Phase I trial in patients progressive at treatment start are very encouraging with significant tumor reduction, complete and partial responses with long lasting disease stabilization of up to 25 months and the virtual lack of relevant toxicities."

About PankoMab-GEX^TM

PankoMab-GEX^TM is a potent humanized and glycooptimized therapeutic antibody (IgG1) recognizing Glycotope's novel carbohydrate-induced conformational TA-MUC1 epitope expressed on the majority of tumor cells in a wide variety of cancers. The epitope comprises a tumor-specific carbohydrate antigen together with the immunodominant peptide region of MUC1, combining high tumor-specificity, high number of binding sites and affinity. It is abundantly present on primary tumors, metastasis and cancer stem cells and virtually absent on normal cells. Main target indications include ovarian, lung, breast and gastrointestinal tumors, and other, mostly with over 90% of the patients and tumor cells. PankoMab-GEX^TM expresses a series of potent anti-tumor modes of action, including antibody-dependent cellular cytotoxicity (ADCC), tumor cell phagocytosis and apoptosis induction, strongly enhanced by glycooptimization through Glycotope's GlycoExpress^TM platform. This allows a significantly improved treatment outcome compared to non-glycooptimized biotherapeutics. PankoMab-GEX^TM is the lead molecule of Glycotopes's GlycoBody technology which represents the Company's treasure box of more than 200 monoclonal antibodies.

About Glycotope

Glycotope, founded 2001 in Berlin, focuses on the development of innovative antibodies for the treatment of various cancer types. These GlycoBodies^TM target glycostructures or carbohydrate-peptide mixed epitopes on cell surfaces. In addition, Glycotope develops so-called BioSuperiors, antibody and non-antibody recombinant biopharmaceuticals with optimized and fully human sugar structures for clinical superiority. Key to the glycooptimization technology is a toolbox of glycoengineered proprietary human cell lines that allow the glycooptimization of proteins in respect to a whole series of different determining sugars and is based on fully human glycosylation. GlycoExpress^TM allows the selection of the most appropriate and best suitable human glycoform of a product and a high yield production superior in reproducibility, quality and yield. Glycooptimization via GlycoExpress^TM provides improved efficacy, bioavailability, immunogenicity and broadens the potential patient populations and indications, as well as providing a much improved cost-effectiveness. Glycotope has currently four products in clinical development from late stage Phase I to late stage Phase II. The Company's additional pipeline includes preclinical non-antibody and antibody biopharmaceuticals for various indications. Together with its subsidiary Glycotope Biotechnology in Heidelberg, Glycotope has evolved into a leading fully integrated glycobiology company, covering the entire workflow from discovery, molecule optimization, clone and process development, preclinical and clinical drug development to GMP production. With more than 160 employees and a strong and broad IP-platform, Glycotope today is one of the largest biotechnology companies in Germany.